Recommendations for optimizing the use of cytology in the diagnosis and management of patients with lung cancer

Q4 Medicine

Revista Espanola de Patologia Pub Date : 2023-01-01 DOI:10.1016/j.patol.2022.04.001

María D. Lozano , Amparo Benito , Tania Labiano , Lara Pijuan , Eva Tejerina , Héctor Torres , Javier Gómez-Román

{"title":"Recommendations for optimizing the use of cytology in the diagnosis and management of patients with lung cancer","authors":"María D. Lozano , Amparo Benito , Tania Labiano , Lara Pijuan , Eva Tejerina , Héctor Torres , Javier Gómez-Román","doi":"10.1016/j.patol.2022.04.001","DOIUrl":null,"url":null,"abstract":"<div><p>Non-small cell lung cancer (NSCLC) is one of the oncological entities with the greatest evolution in molecular diagnosis due to the large number of diagnostic biomarkers and new treatments approved by international regulatory agencies. An accurate, early diagnosis using the least amount of tissue is the goal for the establishing and developing precision medicine for these patients. Rapid on-site evaluation (ROSE) provides cytological samples of optimal quantity and quality for a complete diagnosis of NSCLC. The usefulness of cytological samples has been demonstrated, not only for massive parallel sequencing but also for the quantification of the expression of programmed death-ligand 1 (PD-L1) and tumour mutational burden (TMB).</p><p>Pre-analytical, analytical, and post-analytical recommendations are made for the management and appropriate use of cytological samples in order to obtain all the information necessary for the diagnosis and treatment of patients with NSCLC according to current quality parameters.</p></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Patologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699885522000265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Non-small cell lung cancer (NSCLC) is one of the oncological entities with the greatest evolution in molecular diagnosis due to the large number of diagnostic biomarkers and new treatments approved by international regulatory agencies. An accurate, early diagnosis using the least amount of tissue is the goal for the establishing and developing precision medicine for these patients. Rapid on-site evaluation (ROSE) provides cytological samples of optimal quantity and quality for a complete diagnosis of NSCLC. The usefulness of cytological samples has been demonstrated, not only for massive parallel sequencing but also for the quantification of the expression of programmed death-ligand 1 (PD-L1) and tumour mutational burden (TMB).

Pre-analytical, analytical, and post-analytical recommendations are made for the management and appropriate use of cytological samples in order to obtain all the information necessary for the diagnosis and treatment of patients with NSCLC according to current quality parameters.

查看原文本刊更多论文

建议优化细胞学在肺癌患者诊断和治疗中的应用

非小细胞肺癌癌症（NSCLC）是分子诊断发展最快的肿瘤实体之一，因为国际监管机构批准了大量的诊断生物标志物和新的治疗方法。使用最少的组织进行准确、早期的诊断是为这些患者建立和开发精确医学的目标。快速现场评估（ROSE）为NSCLC的完整诊断提供了最佳数量和质量的细胞学样本。细胞学样本的有用性已经得到证明，不仅用于大规模平行测序，还用于定量程序性死亡配体1（PD-L1）和肿瘤突变负荷（TMB）的表达，并对细胞学样本的管理和适当使用提出分析后建议，以便根据当前的质量参数获得诊断和治疗NSCLC患者所需的所有信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Espanola de Patologia Medicine-Pathology and Forensic Medicine

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

34 days